# Everolimus (Afinitor) Case Study

## Overview
Everolimus is a derivative of rapamycin and acts as a selective inhibitor of the mTORC1 complex.

## DRIFT Modeling Parameters
- **Target:** mTORC1 (via FKBP12 binding)
- **Mechanism:** Allosteric inhibition.
- **DRIFT Config:**
  - `drug_kd`: ~1-2 nM
  - `signaling_nodes`: Direct impact on the `mTOR_state` in DRIFT's integrator.

## Predicted Response
1. **Signaling:** Highly specific inhibition of mTORC1-mediated phosphorylation of S6K1 and 4E-BP1.
2. **Metabolism:** Direct modulation of protein synthesis and lipid metabolism flux constraints.
3. **Phenotype:** Potent growth inhibition with minimal initial impact on upstream AKT phosphorylation (capturing the feedback loop complexities).

## Research Utility
Using DRIFT, researchers can simulate the "rapalog" effect and predict how different metabolic backgrounds (e.g., varying glucose levels) influence mTOR inhibition sensitivity.
